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Human immunodeficiency virus type 1 (HIV-1) Tat is a mediator of viral transcription and is involved in the control of virus
replication. However, associations between HIV-1 Tat diversity and functional effects during primary HIV-1 infection are still
unclear. We estimated selection pressures in tat exon 1 using the mixed-effects model of evolution with 672 viral sequences gen-
erated from 20 patients infected with HIV-1 subtype C (HIV-1C) over 500 days postseroconversion. tat exon 1 residues 3, 4, 21,
24, 29, 39, and 68 were under positive selection, and we established that specific amino acid signature patterns were apparent in
primary HIV-1C infection compared with chronic infection. We assessed the impact of these mutations on long terminal repeat
(LTR) activity and found that Tat activity was negatively affected by the Ala21 substitution identified in 13/20 (65%) of patients,
which reduced LTR activity by 88% (1%) (P< 0.001). The greatest increase in Tat activity was seen with the Gln35/Lys39 double
mutant that resulted in an additional 49% (14%) production of LTR-driven luciferase (P 0.012). There was a moderate posi-
tive correlation between Tat-mediated LTR activity and HIV-1 RNA in plasma (P 0.026; r 0.400) after 180 days postserocon-
version that was reduced by 500 days postseroconversion (P 0.043; r 0.266). Although Tat activation of the LTR is not a
strong predictor of these clinical variables, there are significant linear relationships between Tat transactivation and patients’
plasma viral loads and CD4 counts, highlighting the complex interplay between Tat mutations in early HIV-1C infection.
Global incidence data from 2010 estimate that 2.7 millionpeople were newly infected with human immunodeficiency
virus (HIV), contributing to a prevalence of 34 million, with
subtypeC accounting for themajority ofworldwide infections (1).
Transmission rates are highest during primary infection (2, 3),
and as a transactivator of HIV transcription, the viral protein Tat
is a large contributor to the rate of viral replication. It is widely
accepted that Tat is an importantmediator of HIV type 1 (HIV-1)
disease progression: Tat plays a central role in the regulation of
HIV-1 gene expression by transactivating viral transcription (re-
viewed in reference 4), in addition to altering cellular gene expres-
sion (5–7). Tat interacts with RNA polymerase II (RNAPII) solely
to mediate elongation of viral RNA; in the absence of Tat, full-
length transcripts are rarely produced, as RNAPII prematurely
dissociates from the template during early transcription, leading
to the accumulation of abortive short viral mRNA.
Without external stimuli, latently infected CD4 T cells and
monocytes restrict HIV expression via cellular components that
negatively regulate the proviral long terminal repeat (LTR), sup-
pressing the production of complete viral transcripts (8–10). This
blockade can be relieved by Tat, which is produced from rare
full-length transcripts and binds to the trans-activation response
element (TAR) (11, 12), an RNA secondary structure at the 5= end
of nascent transcripts. The early, inefficient transcription of viral
mRNA is further enhanced by Tat recruiting positively regulating
cellular transcription factors to the 5= LTR, ultimately facilitating
the accumulation of full-length viral mRNA. Transcription is ini-
tially promoted by the modification of chromatin and the acety-
lation of histones by the CREB-binding protein (CBP)/p300 com-
plex (13), recruited to the HIV promoter by Tat (14–16). The
affinity of the CBP/p300 complex for components of the basal
transcription machinery, such as the TATA-binding protein and
transcription factor IIB (17), is subsequently increased through
conformational alteration by interacting directly with Tat. Corre-
sponding acetylation of key Tat residues by the CBP/p300 com-
plex enhances the subsequent engagement of Tat with the positive
transcription elongation factor P-TEFb complex (12, 18, 19),
composed of cyclin T1 and CDK9 subunits, permitting crucial
phosphorylation of serine residues in the C-terminal domain
(CTD) of RNAPII, resulting in complete viral gene expression
(20). Additional phosphorylation events occur between Tat and
cellular transcription factors, such as NF-B and Sp-1 (21, 22),
which play critical roles in the regulation of viral gene transcrip-
tion. Subtype differences exist in the configuration of these and
other transcription factor binding sites within the LTR, which
have been reported to alter the responsiveness of HIV transcrip-
tion to external stimuli: a single NF-B binding site is present in
the promoter of HIV-1 subtype E (HIV-1E), yet subtype B con-
tains two with subtype C containing at least three, but as many as
four, NF-B consensus sequences (23). The variation in the num-
ber of transcription factor-responsive elements in the LTR has
been shown to differentially regulate viral transcription (24) and
replication in a dose-dependent manner upon exposure of HIV-
infected cells to cytokines, such as tumor necrosis factor alpha
(TNF-) (25–27). Furthermore, the transactivation potential of
Tat from different subtypes is not uniform: subtype E and C Tat
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are strongmediators of LTR transcription compared to subtype B
(28), and this is thought to be due to a higher affinity for the TAR
hairpin (28). The half-life of Tat from subtype E is almost twice as
long as that from subtypes B andC, whichmay be a compensatory
mechanism for the reduction in NF-B binding (28). Intrasu-
btype differences also exist, with a recent signature pattern analy-
sis identifying unique residues in Tat, with higher frequencies of
Ala21, Asn24, Lys29, Lys40, and Gln60 fromHIV-1 subtype C (HIV-
1C) circulating in southern India compared to southern Africa
(29, 30).
The restoration of complete viral gene expression by Tat rein-
forces its role as a major contributor to the establishment and
enhancement of HIV replication during primary infection. Dur-
ing this time, plasma viral levels of HIV-1 are between 105 and 108
RNA copies/ml (31, 32), yet the levels decrease by 2 to 3 orders of
magnitude within 4 to 6 months (33, 34). However, prolonged
high viremia has been reported in a subset of patients during pri-
mary HIV-1 subtype C infection, through a yet undefined mech-
anism (35, 36). It is during this primary phase of infection that the
reservoir of latently infected, resting CD4 T cells is established
and that Tat, particularly variants with impaired activity, may
contribute to the formation of a pool of quiescently infected cells
(37).
The critical nature of Tat in controlling virus replication
through augmented gene expression questions the extent towhich
Tat can endure sequence diversity while maintaining function,
particularly during early infection when the establishment of a
productive infection is paramount. It has been reported for HIV
subtype B and simian immunodeficiency virus (SIV) that tat is
one of the earliest viral genes to be under host selection pressure
(38, 39), leading to sequence diversity early in infection, yet Tat
can tolerate up to 40% sequence variation and still conserve its
function (40). Such rapid mutation of viral cytotoxic T lympho-
cyte (CTL) epitopes in Tat, and other viral proteins, constrains
successfulHIV vaccine development. Data on differences between
genes of regulatory and virion-associated HIV proteins suggest
that HIV may actually evolve to permit an immune response
against viral proteins that are not as essential as Tat andRev during
early replication, such as Gag, as a decoy (41). Nevertheless, levels
of anti-Tat antibodies negatively correlate with diseases progres-
sion, suggesting that Tat plays a major role in determining AIDS
progression (42, 43).
The conserved nature of Tat is compatible with its role as an
important target for possible HIV treatments, as well as a logical
vaccine candidate (44, 45). Current phase II trials in South Africa
are evaluating a therapeutic Tat-based vaccine in anti-Tat anti-
body-negative individuals on antiretroviral therapy (ART) with
high CD4 T cell counts (Istituto Superiore di Sanità [ISS] T-003
trial; ClinicalTrials.gov registration no. NCT01513135) (46).
However, the expansion of Tat vaccine trials to incorporate HIV
preventionwill not be possible without a thorough understanding
of the genetic and associated immunogenic characteristics of Tat
in transmitted virus and during primary infection. We hypothe-
sized that Tat diversity would be evident in patients with HIV-1
subtype C primary infection and that subsequent disparities in the
transactivation potential of these Tat variants would be associated
with plasma viral load. To our knowledge, this is the first study to
genetically characterize HIV-1 tat during primary HIV-1C infec-
tion using single-genome amplification. To address this gap in
HIV research, we asked whether HIV-1 subtype C tat exon 1 was
different when comparing primary infection to chronic infection.
MATERIALS AND METHODS
Study population.Patients were enrolled in anHIV-1Cprimary infection
cohort in Botswana (47, 48), and a subset of 20 subjects was selected based
on the stage of HIV infection: eight acutely infected individuals (patient
codeA toH) and 12 randomly selected seroconverters (patient codeOC to
QU) (Table 1). Acutely infected individuals were identified before sero-
conversion by a positive HIV-1 reverse transcription-PCR (RT-PCR) test
with negative HIV-1 serology (Fiebig stage II) (49). Seroconverters were
identified in the early stage ofHIV-1 infection (Fiebig stages IV toVI). The
time of seroconversion (day 0) was estimated as themidpoint between the
last seronegative test and the first seropositive test for the acutely infected
subjects and by the midpoint of the corresponding Fiebig stage for the
recently infected subjects (47). Table 1 provides baseline clinical parame-
ters, demographic information, and sampling characteristics summarized
for the patients enrolled in the acute and early phases of primary infection.
Written informed consent was obtained from all study participants, and
ethical approval for this research was obtained from the Human Research
Development Committee of the Botswana Ministry of Health and the
Office of Human Research Administration at the Harvard School of Pub-
lic Health.
Viral RNA extraction and single-genome amplification. Viral RNA
extraction from plasma samples was carried out using the QIAamp viral
RNA minikit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions followed by single-genome amplification as described previ-
ously (50). Briefly, reverse transcription of viral RNA was performed us-
ing SuperScript III (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. The single-genome amplification was based on the
method of limiting dilutions (51) andwas usedwithminormodifications.
HIV-1C primary infection tat exon 1 sequences are available publically
through GenBank accession numbers JQ895561 to JQ896230.
Phylogenetic relationships of HIV-1C tat exon 1 sequences. To as-
sess the relationships between newly generated quasispecies from the 20
subjects in this study, JModelTest (52) was used to select the optimal
evolutionary model. A maximum likelihood (ML) phylogenetic tree was
constructed using PhyML (53). A SIV tat exon 1 sequence
(Ref.CPZ.US.85.US_Marilyn.AF103) was used to root the tree. The tree
was visualized in FigTree v1.1.2 (http://tree.bio.ed.ac.uk/software/figtree/)
and MEGA5 (54).
MEME.Positive-selection analyses were performed under a likelihood
framework by investigating for selection in a population-wise manner.
Accordingly, signatures of selection were examined using the newly avail-
able mixed-effects model of evolution (MEME) available in HyPhy 2.11
TABLE 1 Characteristics of study subjects over the first 500 days
postseroconversiona
Characteristic
Median value (IQR) unless specified
otherwise for the following patients:
P
value
Acutely infected
(patients A to H)
Early phase of
infection (patients
OC to QU)
Viral load (log10 no. of RNA
copies/ml)
4.95 (4.00–5.52) 4.40 (3.84–4.75) 0.11
CD4 count (no. of cells/l) 337 (258–426) 374 (258–490) 0.72
Age (yr) 31.50 (26.75–34.25) 25.50 (24.75–27.00) 0.11
Sex, no. of females/total no.
of patients (%)
6/8 (75) 9/12 (75) 1.00
Fiebig stage II (II–II) V (V–VI) 0.01
No. of time points sequenced 3.50 (2.75–4.25) 2.00 (1.75–3.00) 0.06
Duration of follow-up (days) 362 (203–381) 279 (179–374) 0.59
No. of sequences 48 (33–73) 23 (16–27) 0.01
a IQR, interquartile range. P values compare the values for acutely infected patients and
patients in the early phase of infection.
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(55–57). We used the Hasegawa-Kishino-Yano (HKY) nucleotide substi-
tution model (58) crossed with the Muse and Gaut 1994 (MG94) codon
model (59). The significance level was set at 0.1 for a site to be considered
under selection. Those sites under positive selection were mapped to the
Tat crystal structure (Protein Data Bank [PDB] accession no. 3MI9) and
visualized using the Visual Molecular Dynamics program (VMD) (60).
The sequence logo was generated with the online web logo tool at the
University of California at Berkeley (UC Berkeley) (http://weblogo
.berkeley.edu).
LANL sequences used for comparisons. Single-patient subtype C se-
quences available in the Los Alamos National Laboratory (LANL) HIV
database (http://www.hiv.lanl.gov/), included 694 subtype C tat exon 1
sequences of the 1,544 total. Chronic infectionHIV-1 subtype C sequence
criteria included the following: (i) stage of infection at the time of sam-
pling that was1,000 days postinfection/seroconversion; (ii) nonrecom-
binantHIV-1 subtype C; and (iii) full-length tat exon 1. This included 183
HIV-1 subtype C chronic infection tat exon 1 sequences retrieved from
the LANL HIV Database (accessed 28 September 2012). The majority of
the available sequences were from southern Africa (n  179); four se-
quences were from India. We assessed phylogenetic clustering of these
sequences in relation to our newly characterized sequences and found that
all study sequences were scattered across the phylogenetic tree with refer-
ence sequences, and no distinct clades or clusters were detected.
Amino acid frequency variation. Single-genome sequences generated
from the earliest available time point postseroconversion were used to
construct a primary infection consensus sequence for each patient. These
20 sequences, in addition to full-length chronic infection (1,000 days
postseroconversion) LANL tat exon 1 subtype C sequences (n  183),
were used in MargFreq (http://sray.med.som.jhmi.edu/SCRoftware
/margfreq/) to generate amino acid frequencies at each codon.Differences
in the primary infection virus were assessed statistically using the two-
tailed Fisher’s exact test with an  of 0.05.
HLA typing ofmajor histocompatibility complex (MHC) class I and
epitope analysis. High-resolution HLA typing was performed for all
study subjects, except subjects OK, ON, and OP, as described previously
(61). All ambiguous positions were resolved by resequencing. Polymor-
phisms outside the targeted exons that could not resolve heterozygote
combinations were refined using a statistical method that calculates an
HLA haplotype given the probability of association with fully resolved
patient HLA class I genotypes at other positions (62). Previously defined
CTL/CD8 epitopes to HIV-1C Tat were obtained from the LANL HIV
Molecular Immunology Database. Putative HLA-restricted epitopes
within subtype C Tat were identified by scanning the patient consensus
sequences for HLA-restricted epitope anchor residue motifs using two
independent bioinformatic tools:Motif Scan forHIVHLAanchor residue
motifs (http://www.hiv.lanl.gov/content/immunology/motif_scan/motif
_scan) and Epipred (63).
GenerationofTat expression clones.A tat exon1 consensus sequence
was generated for each patient from viral quasispecies sequenced during
primary infection. tat exon 2, which is not required for transactivation of
the HIV-1 LTR sequence, was derived from the HIV-1 subtype C consen-
sus. tat sequences were cloned into the pGen2.1 vector, allowing for Tat
expression via the cytomegalovirus (CMV) promoter. Introducing the
relevant nucleotide substitutions into tat exon 1 of the subtype C consen-
sus full-length Tat vector generated pGen2.1-	Tat clones containing a
single amino acid mutation. All cloning and site-directed mutagenesis
were performed by Genscript (Piscataway, NJ, USA).
Cell culture and transfections. TZM-bl cells, obtained from the NIH
AIDS Reagents Program, are HeLa cell derivatives that stably express

-galactosidase and firefly luciferase under the control of the HIV-1 LTR
(64–68). The cells were cultured in Dulbecco modified Eagle medium
(DMEM) supplementedwith 10% fetal bovine serum, 100Uof penicillin/
ml, 100 mg of streptomycin/ml, 2 mM L-glutamine, and 0.1 mM nones-
sential amino acids. No selective antibiotics were required for the main-
tenance of firefly luciferase expression. TZM-bl cells were transfected by
electroporation with 1 g of pGen2.1-Tat per 106 cells using the Neon
system (Invitrogen, Carlsbad, CA) with two pulses of 1,200 V for 20 ms.
For a negative control, a pGen2.1 vector lacking both tat exons (pGen2.1-
empty) was similarly transfected into TZM-bl cells. The cells were ali-
quoted at 2  104 per well in 100 l of supplemented DMEM without
antibiotics in 96-well plates. To normalize for potential differences in
transfection efficiency and variation in the number of cells plated, 4g of
pRL-SV40 (Promega), a Renilla luciferase-expressing construct under the
control of the simian virus 40 (SV40) promoter, which isminimally trans-
activated by Tat, was added to a master batch of TZM-bl cells before they
were aliquoted for transfection with a pGen2.1-Tat construct.
Luciferase assay. After 48 h, the cells were lysed in Dual-Glo firefly
luciferase buffer (Promega) and incubated at room temperature for 10
min, and firefly luciferase activity was determined using a PerkinElmer
luminometer. Firefly luciferase activity was then simultaneously
quenched by the addition of the Dual-Glo Renilla luciferase substrate,
which was also incubated at room temperature for 10 min, and activity
was similarly determined by the luminometer.
Data and statistical analyses. Firefly luciferase values were normal-
ized to Renilla luciferase activity. The subtype C consensus Tat construct
was assigned the value 1, and differences in LTR transactivation by patient
Tat constructs were calculated relative to the consensus and are given as
the median difference in expression interquartile range. A normal dis-
tribution of the luciferase data was assessed by the D’Agostino and Pear-
son omnibus normality test (69), and normalized luciferase data were
log10 transformed for use in linear regression and parametric analyses. A
two-tailed Student’s t test was performed on the transformed, normalized
luciferase data between the Tat activity for consensus HIV-1C compared
to each one of the Tat constructs from the patients. The Pearson product-
moment correlation coefficient was used to determine the strength of
association or correlation between Tat transactivation and patients’
plasma RNA viral loads, CD4 counts, and proviral loads. P values were
corrected for multiple comparisons using the Benjamini-Hochberg
method to control the false discovery rate (70). Adequate quasispecies
sampling from each patient was determined by estimating the likelihood
of missing infrequent viral variants present in patient plasma: with n sin-
gle genomes sequenced, the probability (P) of missing a quasispecies after
screening n genomes is calculated as f 1 (1 P1/n) when the variant
comprises a fraction f (or less) of the virus population (71).
RESULTS
Minimal Tat diversity during primary infection. The phyloge-
netic relationships between HIV-1C tat exon 1 viral quasispecies
from 20 subjects during primary infection are shown in Fig. 1. The
maximum likelihood tree highlights distinct patient-specific clus-
ters (except the subject pair OK/OI, as described previously [50]),
and a high level of homogeneity between quasispecies over 500
days postseroconversion.
Positive selection of Tat residues during primary infection.
We employed an evolutionary framework to determine whether
any specific sites in tat exon 1 are under positive selection during
primary infection. Themixed-effectsmodel of evolution (MEME)
detects positively selected sites despite themajority of lineages at a
given site evolving under purifying selection, which may mask
potential episodic selection acting on a small proportion of lin-
eages. Our analysis found that residues 3, 4, 21, 24, 29, 39, and 68
of tat exon 1 were undergoing positive selection during primary
infection (Table 2). We observed positive selection affecting a
small subset of branches at sites 3 and 39 and, to some extent, at
sites 24 and 29. In contrast, positive selection appears to be perva-
sive, in a rather large proportion of branches, at sites 4, 21, and 68
and with various levels at sites 24 and 29 (Table 2). Furthermore,
our results support recently published data revealing an epistatic
Rossenkhan et al.
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FIG 1 Maximum likelihood phylogenetic analysis of primary infectionHIV-1 subtype C tat exon 1 viral quasispecies. A phylogenetic tree was constructed using
PhyML (16) and the TVMIGmodel (TVM stands for transversion model, I is the proportion of invariable sites, and G is the gamma distribution across the
branches) for nucleotide substitution. The tree was visualized in FigTree andMEGA5 (45). SIV sequence (Ref.CPZ.US.85.US_Marilyn.AF103) was used to root
the tree. The data are shown for 0 to 90,90 to 180, and180 to 500 days postseroconversion (d p/s).
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interaction between residues in Tat (72). We did not observe in-
dividual changes at either Leu35 or Gln39, but we determined that
all sequenced patient quasispecies from patient F carried genes
encoding both the L35Q and Q39L coevolving mutations. Al-
though MEME identified only residue 39 as positively selected,
given the conservative approach of this model, a possible explana-
tion is that two-nucleotide changes were necessary for the Q39L
transition (CAG to TTG) in patient F, while only one-nucleotide
change was necessary for L35Q (CAG to CAA).
To appreciate the spatial interactions of positively selected res-
idues 3, 4, 21, 24, 29, and 39 in the context of the Tat quaternary
structure, we mapped these residues to the only high-resolution
(2.1-Å) crystal structure of Tat available (Fig. 2A) (73). We were
unable to map residue 68, because reliable crystal structures for
that region are not defined. The majority of selected amino acid
residues lie on the Tat activation domain (amino acids 1 to 48)
that interacts with cellular proteins such as the positive transcrip-
tion elongation factor P-TEFb; therefore, we might expect
changes in these residues to have functional consequences. In par-
ticular, residues 3 and 4 reside on the critical acidic/proline-rich
region, and residues 21, 24, 29, and 39 reside on the cysteine-rich/
Zn2 finger region of the activation domain, which mediates the
coordination of Zn2 ions.We also observed high diversity within
positively selected sites, probably related to the fact that those sites
are found to be under diversifying selection (Fig. 2B). Two of the
more diverse codon positions (sites 24 and 29) exhibiting a bal-
anced proportion of branches under 
 and 
, which suggests
that a substantial amount of both positive and negative selection is
occurring on the branches, though over 50% are under negative
selection (Table 2 and Fig. 2B).
Frequency of Tat amino acid residues differs between pri-
mary and chronic HIV infection at specific sites. Signature pat-
tern differences were apparent in Tat from the primary infection
cohort comparedwith chronicHIV-1C infection by assessment of
amino acid frequencies at each codon position of tat exon 1. Glu2
was less frequent during primary infection (75%) compared to
chronic infection (93%) (P  0.020), which was complemented
by a significantly greater prevalence of Asp2 in primary infection
(25%) compared to in chronic infection (7%). Only two of seven
sites that were found to be under positive selection during primary
infection showed significant differences compared with chronic
infection sequences: 15%Lys24 in primary infection versus 44% in
chronic infection (P 0.015) and 30% Ser24 in primary infection
versus 3% in chronic infection (P 0.001). Significant differences
were also identified at Ala29, present in 10% of primary infection
clinical isolates yet only 1% in those chronically infected with
HIV-1C (P 0.048).
Additionally, we found a statistically significant difference be-
tween primary infection and chronic infection tat exon 1 amino
acids at position 59 in terms of the amino acid charge in the two
stages of HIV infection. The effect of the amino acid in side chain
hydrophobicity/hydrophilicity from the chronic infection se-
quences are not well understood, but this change was observed in
the auxiliary region of tat exon 1 (amino acids 58 to 71). During
primary infection, tat exon 1 had significantly more neutral resi-
dues at position 59 than in chronic infection, with the hydrophilic
Pro59 residue being the most prevalent. Only 6 (3%) sequences
from chronic infection had a neutral amino acid at position 59
compared with 15% of our newly characterized tat exon 1 se-
quences (P 0.046 by Fisher’s exact test).
Amino acid substitutions in Tat associate with HLA. CTL
responses have been mapped to only a small number of HIV-1
subtype C Tat epitopes. To systematically address the role of HLA
in influencing intrapatient amino acid diversity during primary
infection, we analyzed single-genome sequencing data to assess
substitutions in Tat, compared to the subtype C consensus se-
quence (Fig. 3). In addition to the functional data available from
LANL, we employed two predictive analyses, MotifScan and
Epipred, to discern regions that might be under immune pressure
based on the HLA genotypes of the patients. There were only two
instances where the transmitted virus had the wild-type Tat resi-
due and mutated over the first 500 days postseroconversion, both
of which were potentially HLA restricted: in patient OC, the
switch from His29 to Pro29 or Arg29 by 208 days postseroconver-
sion was restricted by both HLA-A*03:01 and HLA-A*68:02; by
411 days postseroconversion, patient OS had switched to Asp24,
completely replacing the wild-type Lys24 residue, which was re-
stricted byHLA-B*35:01. Both of these substitutions occurred in a
region that has been identified as immunodominant in subtype C
Tat (74). The conserved region, comprising the protein transduc-
tion domain, 47-YGRKKRRQRR-56 and the nuclear localization
signal, 48-GRKKR-52, was highly conserved during primary in-
TABLE 2 MEME selection for tat exon 1 from 20 patients over the first 500 days postseroconversion
Codon Wild-type residue Replacement residue(s)
MLEa of the following:
P valuegb 
c Pr
d 
e Pr
f
3 Glu Asp 5.00 109 1.00 1015 9.13 101 9.51 0.087 0.036
4 Pro Gln/Ile 5.00 109 54.99 109 1.00 109 1.50 1.00 0.070
21 Pro Ala 4.00 107 4.00 107 1.26 101 2.34 0.874 0.033
24 Lys His/Asn/Pro/Ser/Thr 9.92 101 3.60 102 5.75 101 26.12 0.425 0.003
29 His Ala/Glu/Ile/Lys/Asn/Pro/Gln/Arg 8.23 101 4.36 106 6.76 101 49.51 0.324 0.001
39 Gln Leu 5.00 109 3.75 1016 9.80 101 30.76 0.020 0.031
68 Leu Pro/Ser 5.00 109 4.98 109 1.00 109 2.34 1.00 0.021
a MLE, maximum likelihood estimate.
b  is the synonymous substitution rate.
c 
 is the nonsynonymous substitution rate for the branch class with 
 .
d Pr
 is the proportion of sites evolving at 
.
e 
 is the nonsynonymous rate for the branch class with 
.
f Pr
 is the proportion of sites evolving at 
.
g P values comparing whether 
  .
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FIG 2 Positive selected Tat residues in context. (A) HIV-1 subtype B (HXB2) crystal structure with positively selected subtype C Tat sites mapped in relation to
cyclin T1. Six out of seven sites were mapped (red), and variation in subtype C during primary infection is shown compared to the residue present in the HIV-1
HXB2 strain (bold type). (B) Sequence logo showing the Tat amino acid diversity observed at positions 1 to 48. The three regions of tat exon 1 are highlighted:
region I (amino acids 1 to 21), an acidic/proline-rich region; region II (amino acids 22 to 37), a cysteine-rich/Zn2 F region; and region III (amino acids 38 to 48),
containing conserved phenylalanine (F).
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fection, with only two instances of mutation: R53G in patient OS,
and S57R, flanking the conserved region, in patient QR. Both
changes, present at the earliest time point and maintained for at
least the first 500 days postseroconversion, were predicted to be
under HLA restriction by Cw*04:01and A31:01, respectively.
HIV-1C interpatient polymorphisms significantly impact
LTR transactivation. A number of patients in the primary infec-
tion cohort contained amino acid residues that differed from the
HIV-1 subtype C consensus at sites identified by MEME as being
under positive selection. On the basis of these data, we introduced
the corresponding single-amino-acid changes into tat exon 1 of
the subtype C consensus to determine the functional effects of
these positively selected sites. The majority of these single poly-
morphisms had a detrimental impact on LTR activation by Tat
(Fig. 4A). The greatest impact on Tat was seen with the Ala21 that
was identified in 13/25 (65%) patients, which reduced LTR activ-
ity by 88% (1%) (P  0.001), which was less than a 2.5-fold
increase above background luciferase levels seen with the
pGen2.1-empty vector control. Conversely, the greatest increase
in Tat activity was seen with the Gln35/Lys39 double mutant that
resulted in an additional 49% (14%) production of LTR-driven
luciferase (P 0.012). It has previously been reported that Gln35
and Lys39 coevolve in vivo and that mutation of either residue
results in a defective virus (72). Our data recapitulate this by
showing that Gln35 reduces LTR activation by 87% (3%) (P 
0.001) and Lys39 by 83% (1%) (P  0.001) compared to the
wild-type Tat construct.
Patient-derived Tat exhibits functional diversity during pri-
mary infection. Compensatory mutations may maintain protein
structure and function when deleterious changes occur at other
residues, so we chose to determine the LTR transactivation capac-
ity in the context of the full-length tat exon 1 from our cohort of
patients during HIV-1C primary infection relative to the activity
of the HIV-1 subtype C consensus Tat (Fig. 4B). Tat from patients
OG, OP, and OS and Tat expressed by patient OC at 27 days
postseroconversion demonstrated no significant change in lucif-
erase expression compared to the HIV-1C consensus Tat. At 208
days postseroconversion, patient OC expressed three Tat quasi-
species that differed at a single amino acid, encoding either His29,
which was dominant at earlier time points and had no significant
effect on LTR activity, or Arg32 or Pro32. The largest decrease in
Tat activity across all patients, relative to the subtype C consensus,
was seen with the OC patient Tat that contained the Pro29 muta-
tion, resulting in a 79% (4%) (P 0.001) decrease in LTR acti-
vation. Conversely, the Arg29 substitution significantly upregu-
lated LTR-luciferase expression by 55% (14%) (P 0.008). The
only other significant increase in Tat transactivation was seen in
patient D, resulting in a 73% (9%) (P 0.001) upregulation of
expression.
The Tat sequence for patient C contained a three-nucleotide
insertion that introduced an additional arginine residue into the
transactivation domain, subsequently increasing LTR activity by
22% (6%) (P  0.034) compared to the patient C Tat without
the insertion, yet remained significantly less active than the con-
sensus C Tat. Of the two patients that demonstrated sequence
diversity over time, patient OS expressed the wild-type Lys24 res-
idue at day 203 days postseroconversion, which demonstrated no
difference in Tat transactivation activity compared to the consen-
FIG 3 tat exon 1 during primary HIV-1 subtype C infection and putative HLA epitope determined by Epipred (shaded) and MotifScan (white). MEME
positively selected sites are highlighted in gray. The conserved region, comprising the nuclear localization signal (48-GRKKR-52) and protein transduc-
tion domain (47-YGRKKRRQRR-56) is shown at the top of the figure. Amino acid residues identical to those in the conserved region are indicated by periods
for the sequences from the patients. Due to the arginine (R) insertion in patient C, gaps were introduced tomaximize alignment and are indicated by dashes. No
HLA typing data were available for patients OK, ON, and OP.
FIG 4 Relative changes in LTR activity. (A) Changes in LTR-luciferase activity by individual Tat mutations were determined relative to the HIV-1 subtype C
consensus sequence at 48 h posttransfection. The pGen2.1 empty vector was included as a negative control. Values are the medians from four independent
experiments, and the error bars indicate the interquartile ranges. (B) Changes in LTR-luciferase activity by patient-derived Tat were determined relative to the
subtype C consensus sequence at 48 h posttransfection. The pGen2.1 empty vector was included as a negative control. Values are the medians from four
independent experiments, and the error bars indicate the interquartile ranges. Statistical significance is indicated as follows: , P 0.05; , P 0.01; , P
0.001.
tat Exon 1 Function during Primary Subtype C Infection
May 2013 Volume 87 Number 10 jvi.asm.org 5739
 o
n
 April 3, 2016 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
sus. Yet by 411 days postseroconversion, complete replacement
with Asn24 (A-to-T change at the third nucleotide of codon 24)
reduced Tat activity by 63% (2%) (P  0.021) compared to
activity at 203 days postseroconversion. Similarly, patient OC ex-
pressed a Tat variant at 27 days postseroconversion that transac-
tivated the LTR at a level similar to that of the HIV-1 consensus C.
However, by 208 days postseroconversion, 11 of 35 sequences
(31.4%) had Arg29 and 5 sequences (14.3%) had Pro29, with the
remaining 19 sequences (54.3%) retaining thewild-typeHis29 res-
idue. The Arg29 and Pro29 mutations had opposing effects on Tat
activity: a switch to proline at position 29 reduced Tat activity by
78% (4%) (P  0.027), whereas an arginine residue increased
Tat activity by 64% (15%) (P  0.164) compared to the His29
Tat variant that predominated in patient OC at 27 days postsero-
conversion. The nonsignificantP value for the large change in LTR
activity by the Arg29 mutation is likely due to the high standard
deviation seen in the luciferase assay data performed using the Tat
construct from patient OC 27 days postseroconversion.
Association of LTR transactivation by Tat with clinical char-
acteristics. The relationships between the Tat-mediated LTR ac-
tivity and patient plasma viral loads, CD4 counts, and proviral
loads over the first 180 days postseroconversionwere examined by
the Pearson product-moment correlation coefficient and linear
regression. There was amoderate positive correlationwith plasma
viral load (P  0.026; r  0.400) (Fig. 5A) and a weak negative
correlationwithCD4 count (P 0.090; r0.315) (Fig. 5B), but
not with proviral DNA load (P  0.229; r  0.255) (Fig. 5C).
Three patients (patients ON, OP, and OS) did not have clinical
data available before 180 days, so they were excluded from the
analysis. Later set point viral loads, up to 500 days postserocon-
version, were more weakly correlated with Tat-mediated LTR ac-
tivity (P 0.043; r 0.266) (Fig. 5D) and showed a weaker neg-
ative correlation with CD4 count (P  0.040; r  0.274) (Fig.
5E). There remained no correlation with proviral load (P 0.173;
r0.209) (Fig. 5F). While the independent linear relationships
between the Tat-mediated luciferase expression and patients’
plasma viral loads and CD4 counts are significant, Tat activation
of the LTRmay not be a strong predictor of these clinical variables.
DISCUSSION
To our knowledge, this is the first in-depth functional character-
ization of tat exon 1 during primary HIV-1 subtype C infection.
We employed the recently developedMEMEmethod for detecting
selection acting on HIV-1 subtype C Tat sequences during pri-
mary infection. TheMEMEmethod has advantages over previous
methods, as it is able to detect sites under diversifying selection on
most lineages of the underlying phylogeny (pervasive selection),
as well as those sites under selection only on a small proportion of
lineages (episodic selection). Usually, traditional selection detec-
tion methods mask sites that are subjected to selection in a small
proportion of lineages, which hampers the power to observe early
dynamic processes. Seven sites were found to be under positive
selection with various levels of pervasiveness on the underlying
phylogeny. For instance, sites 3 and 39 are involved in Tat regions
that are essential for its catalytic and regulatory activities, respec-
tively. The finding that these sites are being selected on a small
proportion of sites might indicate a change in Tat performance
and thus have functional consequences. Similarly, we identified
sites (sites 24 and 29) under positive selection in about 50% of
lineages, and the proportions of Lys24, Ser24, and Ala29 differed in
primary and chronic infection. This finding suggests different se-
lective pressure in primary and chronic HIV-1C infection and is
supported by functional analysis showing that these amino acid
FIG 5 Correlation of Tat activity with clinical variables. A Pearson product-moment correlation coefficient and linear regression (solid line) were performed to
determine a predictive association between the median LTR-luciferase activity (in relative light units [RLU]) and the patient plasma viral loads (A), CD4 counts
(B), and proviral loads (C) over the first 180 days postseroconversion and the patient plasma viral loads (D), CD4 counts (E), and proviral loads (F) over the first
500 days postseroconversion. The 95% confidence intervals are shown as dotted lines.
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substitutions have significant functional consequences for Tat
transactivation.
We found that site 39 is under episodic positive selection on a
small proportion of branches (Pr
 0.020) and is also engaged
in bidirectional epistatic interactions with site 35 (posterior prob-
ability 1), a phenomenon that has already been reported in vivo
(72). This reinforces the results of our selection analysis, since a
mutation at site 39 results in reduced LTR activation in our sub-
sequent functional assays; naturally, most of the lineages show site
39 to be under negative or purifying selection, suggesting that this
position is constrained by its epistatic interaction with site 35.
Given that the majority of HIV-1 Tat data available are from pop-
ulation sequencing, to our knowledge, this is the first report dem-
onstrating that the Glu35 and Lys39 substitutions are epistatically
linked in the same RNA molecule.
On the basis of theMEMEdata, we performed functional anal-
ysis of individual Tat amino acid substitutions at sites identified as
being under positive selection during primary infection. The ma-
jority of these changes had a significant negative impact on the
transactivation potential of Tat to activate the LTR. Only two sin-
gle alterations, P3I and H29A significantly increased LTR tran-
scription compared to the wild-type HIV-1 subtype C Tat, and
these substitutions were present in the same patient, patient QR.
However, expression of this patient’s full-length tat exon 1 re-
sulted in a significant 16% reduction in LTR activity, highlighting
the complex interplay between mutations in Tat. This is exempli-
fied by the epistatic substitutions at Lys35 and Glu39 that individ-
ually abrogate important interactions between Tat and P-TEFb
(72) but when coevolving, restore the transactivation activity to
beyond wild-type levels. A number of Tat residues in exon 1 have
been identified as crucial for their ability to recruit CBP/p300 and
P-TEFb and to transactivate the LTR. Numerous sites have been
reported to undergo posttranslational modification by cellular
proteins. (i) The arginine-rich motif, involved in RNA binding, is
modified bymethylation and acetylation at a string of residues. (ii)
Lys50 is acetylated by p300 after couplingwith Tat (75). (iii)Meth-
ylation occurs at Lys51 by the lysine methyltransferase KMT7 (76,
77). (iv) Methylation occurs at Arg52 and Arg53 by the protein
arginine N-methyltransferase PRMT6 (78). The arginine-rich
motif lies within the transduction domain, which was completely
conserved in all patients except for the R53G substitution ob-
served in patientOS, whichwas potentially restricted byCw*04:01
and maintained longitudinally. Tat from this patient containing
the Arg53 substitution had no discernible effect on LTR transcrip-
tion in functional assays. Autoacetylation by Tat occurs specifi-
cally on Lys41 and Lys71 (79), two residues that are completely
conserved in our primary HIV-1C infection data. The absence of
Lys41 reduces virus replication by preventing the enhancement of
histone acetyltransferase activity by p300 (79).
Phosphorylation occurs at Ser16 and Ser46 by cyclin-dependent
kinase 2 (CDK2) (80) and at Ser62, Thr64, and Ser68 by protein
kinase R (PKR) in subtype B (81), yet variability in the prevalence
of these serine residues in primary HIV-1C infection suggests that
subtype differences may exist. Amino acid substitutions at resi-
dues 16 and 46 are reported to significantly reduce virus produc-
tion in vitro, and these serine residues were conserved in our co-
hort except for a S46Y substitution observed in patient E, a switch
that was previously identified to be restricted by the same HLA
found in patient E, B*15:03 (80). Of those Tat residues phosphor-
ylated by PKR, only Ser62 is conserved in our primary infection
cohort; Thr64 is present as Lys64 or Asp64, and Ser68 is present as
Leu68 or Pro68. In subtype B, the importance of retaining these
phosphorylation sites has been demonstrated: a 42% reduction in
LTR activity was reported with either an A64T or A68S substitu-
tion, with a Tat double mutant reducing transactivation by 59%
(81). However, these deleterious mutations were in the context of
an HIV-1B Tat; despite the high prevalence of Thr64 and Ser68
substitutions in our primary infection cohort, subtype C Tat has
been shown to be a more potent transactivator than its subtype B
counterpart. Itmay be that compensatorymutations exist inHIV-
1C, as our functional data demonstrated that substituting Ser68
with Pro68 actually significantly increased LTR transcription by
250%.
The established coevolution of sites Glu35 and Lys39 was ob-
served in one of our patients, and functional analysis in the con-
text of a subtype CTat background reinforced the negative impact
of mutating either residue individually, with rescue of the wild-
type phenotype achieved by the introduction of the corresponding
compensatory substitution. Glu35 and Lys39 independently con-
tribute to distinct aspects of Tat-mediated transcription: binding
to P-TEFb and promoting phosphorylation of RNAPII by
P-TEFb, respectively (72). The single L39Qmutant will retain the
ability to interact with P-TEFb yet will fail to phosphorylate the
CTD of RNAPII, whereas the Q35L substitution abrogates any
binding with P-TEFb (72). The importance of invariant cysteine
residues in Tat, which are highly conserved between subtypes, has
been extensively studied (82). Of the seven cysteines, only Cys31
has been shown to be dispensable for Tat transactivation, while
the substitution of any other cysteine residue between sites 22 and
37 abolishes Tat function. DNAbinding and transcriptional activ-
ity of the NF-B p65 subunit is enhanced through direct binding
to Tat via this cysteine-rich region and is complemented by a
corresponding association between the arginine-richmotif of Tat,
which sequesters the NF-B inhibitor, IB, allowing the tran-
scription factor to relocalize to the nucleus. All of the crucial cys-
teines are entirely conserved during primary HIV-1C infection,
with the variable Cys31 present only in patient D, with all other
patients expressing the characteristic subtype C Ser31 residue. The
adjacent, invariable Cys30 forms a CC chemokine motif in other
HIV-1 subtypes that retain the Cys31 (83), which is reported to be
important for monocyte chemotaxis and subsequent interleukin
10 (IL-10) induction (84). Abrogated binding of the CS motif in
subtype C to chemokine (CC motif) receptor 2b (CCR2b) pre-
vents downstream signaling that culminates in cytokine induction
and the upregulation of chemokine (CXC motif) receptor 4
(CXCR4) on CD4 T cells (83). Although patient D harbored the
CC motif and displayed significantly higher levels of LTR induc-
tion in comparison to the wild-type subtype C consensus Tat, it
has previously been shown that substituting the Ser31 residue for
Cys31 does not alter transactivation potential in subtype C (83).
The retention of serine at this site may have yet unidentified func-
tional importance and could potentially act as an alternative phos-
phorylation site.
Other subtype differences exist in sites that have a less estab-
lished role inmediating LTR transactivation. Selection forArg23 in
HIV-1 subtype BTat confers a replicative advantage, yet Arg23 was
the predominant residue in primary subtype C infection and
showed no significant difference in prevalence with chronic infec-
tion (P 0.778 by Fisher’s exact test). We observed low frequen-
cies of Ala21, Asn24, Lys29, Lys40, andGln60, suggesting our data are
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in agreement with a recent report identifying unique signature
residues for HIV-1C in southern India compared to southern Af-
rica. However, we also identified amino acid frequency variations
at sites 24 and 29 during primary infection compared to chronic
HIV-1C, with a significant increase in Ser24 and Ala29 in our co-
hort. Removal of the four tat exon 1 sequences from chronic in-
fection viruses originating in India did not alter the significance of
our results. Heterogeneity withinHIV-1C tat exon 1 coupled with
the variation seen at different stages of infection suggest deviating
evolutionary paths for two geographically distinct clusters of sub-
type C, reinforcing the need for comparative characterization of
these subepidemics.
We recently found that tat exon 1 intrapatient diversity was
associated with plasma viral loads at baseline (r2  0.505; P 
0.044) and at later stages of infection, between 181 and 500 days
postseroconversion (r2  0.516; P  0.039) (50). With the need
for Tat activity to be determined in the context of potentially un-
known compensatory substitutions, we chose to evaluate the as-
sociation between patient tat exon 1 and plasma viral load, CD4
count, and proviral load during the first 500 days postseroconver-
sion. Although the correlation betweenTat-mediated LTR activity
and viral load was not strong, our results show that Tat transacti-
vation is a significant contributor to plasma viral load and CD4
count in primary infection, but not to proviral load. However, a
limitation to our approachprevented us frommatching a patient’s
HIV-1 LTR sequence with the associated tat exon 1, instead rely-
ing on an integrated HIV-1B LTR-driven luciferase reporter in
TZM-bl cells. The original study (50) targeted diversity and diver-
sification of accessory genes and was designed to produce an am-
plicon that extended from the start of the vif open reading frame to
the end of vpu, which encompassed tat exon 1 but does not span
tat exon 2. The spatial separation of tat exon 2 also precluded its
inclusion in this analysis. Although we may have identified a
stronger correlation between Tat transactivation of its autologous
LTR with viral and proviral loads and CD4 count during primary
infection, our use of a standardized LTR allowed us to evaluate the
impact of subtype C Tat mutations without the additional vari-
ability in promoter transactivation arising from potential LTR
substitutions.
An additional limitation of this study was the difference in the
median number of sequences generated for those with acute
HIV-1C infection compared to those in the later stages of primary
infection (47 versus 23 sequences, respectively; P  0.01). How-
ever, we estimated that there is 90% likelihood that Tat quasispe-
cies would have been missed if it comprised 10% of the virus
population when sequencing 23 single genomes and 5% of the
populationwhen sequencing 47 genomes. Conversely, we are con-
fident that we were able to isolate quasispecies from an average of
90% of the circulating virus in the 20 patients with primary
HIV-1C infection. It should be noted that a constraint exists due
to the overlapping nature of nonstructural genes, making it diffi-
cult to assign specific mutational events to specific proteins. The
overlap between the first exon of tat and vpu or revwas assessed for
evidence of positive selection: although there were instances of an
amino acid change observed in the vpu or rev reading frames, no
evidence of positive selection was found in these genes using the
same MEME analysis as described for tat. Furthermore, the sec-
ond exon of tat, which inhibits splicing (85–87), has been shown
to be involved in the cellular uptake of exogenousTat protein (88),
and may contribute to viral infectivity and to binding to cell sur-
face integrins and have a critical role in activating NF-B (89–92).
Other than associations with previous reported immunodom-
inant regions in HIV-1 subtype C Tat (74, 93–98), the HLA data
presented here were predicted based on searching patients’ Tat
sequences for all known HLA anchor residue motifs and associat-
ing the findings with patient HLA genotypes. Within five unique
epitopes identified for subtype C tat exon 1 and associated with a
particular HLA genotype, there is a clear disparity with the extent
of data available for subtype B, which has to be addressed.
Subtype C Tat has been established as a more potent transac-
tivator than its subtype B counterpart, yet it is functionally defi-
cient in mediating chemotaxis and cytokine dysregulation in
monocytes, a key aspect of HIV pathogenesis maintained by other
subtypes (28, 83). Our results suggest that genetic and functional
differences are also apparent between primary and chronic infec-
tion, with specific residues under evolutionary pressure. The sig-
nificant, albeit nonlinear, relationship between Tat transactiva-
tion and plasma viral load during the first 500 days
postseroconversion emphasize its role as a major mediator of vi-
rus replication in early infection. Increased understanding of the
evolution and dynamics of HIV-1C Tat is crucial for Tat-based
vaccine advancement. The functional effects highlight a complex
interplay between individual viral mutations in early HIV-1C in-
fection.
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